Skip to main content

Table 1 Epigenetic writers and erasers approved for treatment or in clinical trial in cancer treatment

From: Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response

 

Drug name

Commercial name

Class

Company

FDA-approved indication

Epigenetic Writers

Azacitidine

Vidaza

DNMTi

Celgene Corp

AML, CML, MDS

5-Aza-2′-deoxycytadine

Dacogen

DNMTi

Eisai

AML, CML, MDS

Tazemetostat

Tazverik

HMTi

Epizyme Inc

Epithelioid Sarcoma*

Epigenetic Erasers

Panobinostat

Farydak

HDACi

Novartis

Multiple Myeloma

Vorinostat

Zolinza

pan-HDACi

Merk

CTCL

Belinostat

Beleodaq

pan-HDACi

Spectrum pharmaceuticals

PTCL

Romidepsin

Istodax

Class I HDACi

Celgene

CTCL/PTCL

Chidamide

Epidaza

pan-HDACi

Chipscreen Biosciences

PTCL

  1. Abbreviations: DNMTi: DNA methyltransferase inhibitors: HMTi: Histone methyltransferase inhibitor: HDACi: Histone deacteylase inhibitors: AML: Acute myeloid leukemia: CML: MDS: Myeloid dysplastic syndrome: CTCL: Cutaneous T-cell Lymphoma: PTCL: Peripheral T cell lymphoma. * approved in China only